Literature DB >> 3752981

Vancomycin enhancement of experimental tobramycin nephrotoxicity.

C A Wood, S J Kohlhepp, P W Kohnen, D C Houghton, D N Gilbert.   

Abstract

The influence of vancomycin on tobramycin nephrotoxicity was assessed in male Fischer rats. Treatment groups included controls receiving diluent and groups receiving vancomycin alone at a dosage of 200 mg/kg (body weight) per day, tobramycin alone at a dosage of 80 mg/kg per day, and a combination of vancomycin and tobramycin at the above dosages. All regimens were injected on a twice-a-day schedule. The animals were sacrificed on days 1, 3, 10, 14, 17, and 21. When compared with controls, animals receiving vancomycin alone exhibited no detectable renal toxicity. Compared with the case with controls, tobramycin alone was toxic, as manifested by lower mean animal weights, increased blood urea nitrogen concentrations on days 14 and 17 (P less than 0.005), increased serum creatinine concentrations on days 17 and 21 (P less than 0.005), and the presence of renal cortical tubular necrosis and regeneration. When compared with tobramycin alone, the combination of vancomycin and tobramycin caused earlier and more severe toxicity. By day 10, the magnitude of weight loss, the rise in blood urea nitrogen, and the increase in serum creatinine concentration were all greater in the rats given the combination of vancomycin plus tobramycin than in the animals given tobramycin alone (P less than 0.005). In addition, there was more proximal tubular necrosis and regeneration in rats given vancomycin plus tobramycin compared with those given tobramycin alone. In this animal model, vancomycin alone caused no detectable renal injury, tobramycin alone produced minimal proximal tubular damage, and the combination of vancomycin and tobramycin resulted in a greater degree of kidney injury than observed with tobramycin alone.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3752981      PMCID: PMC176427          DOI: 10.1128/AAC.30.1.20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  The treatment of severe staphylococcal infections with vancomycin.

Authors:  D W WOODLEY; W H HALL
Journal:  Ann Intern Med       Date:  1961-08       Impact factor: 25.391

2.  The nephrotoxicity of antimicrobial agents (second of three parts).

Authors:  G B Appel; H C Neu
Journal:  N Engl J Med       Date:  1977-03-31       Impact factor: 91.245

3.  Optimal therapy for enterococcal endocarditis.

Authors:  J Herzstein; J L Ryan; R J Mangi; T P Greco; V T Andriole
Journal:  Am J Med       Date:  1984-02       Impact factor: 4.965

4.  Comparative nephrotoxicity of gentamicin and tobramycin in rats.

Authors:  D N Gilbert; C Plamp; P Starr; W M Bennet; D C Houghton; G Porter
Journal:  Antimicrob Agents Chemother       Date:  1978-01       Impact factor: 5.191

5.  Enterococcal endocarditis.

Authors:  C J Wilkowske
Journal:  Mayo Clin Proc       Date:  1982-02       Impact factor: 7.616

6.  Toxicology of vancomycin in laboratory animals.

Authors:  J S Wold; S A Turnipseed
Journal:  Rev Infect Dis       Date:  1981 Nov-Dec

7.  Staphylococcus epidermidis causing prosthetic valve endocarditis: microbiologic and clinical observations as guides to therapy.

Authors:  A W Karchmer; G L Archer; W E Dismukes
Journal:  Ann Intern Med       Date:  1983-04       Impact factor: 25.391

8.  Vancomycin toxicity: a prospective study.

Authors:  J A Mellor; J Kingdom; M Cafferkey; C T Keane
Journal:  J Antimicrob Chemother       Date:  1985-06       Impact factor: 5.790

9.  A prospective study of adverse reactions associated with vancomycin therapy.

Authors:  T C Sorrell; P J Collignon
Journal:  J Antimicrob Chemother       Date:  1985-08       Impact factor: 5.790

10.  Vancomycin use--an historical review.

Authors:  R S Griffith
Journal:  J Antimicrob Chemother       Date:  1984-12       Impact factor: 5.790

View more
  31 in total

Review 1.  Antibacterial-induced nephrotoxicity in the newborn.

Authors:  V Fanos; L Cataldi
Journal:  Drug Saf       Date:  1999-03       Impact factor: 5.606

Review 2.  Vancomycin- and erythromycin-induced hearing loss in humans.

Authors:  R E Brummett; K E Fox
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

Review 3.  Once-daily aminoglycoside therapy.

Authors:  D N Gilbert
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

4.  Intrarenal distribution of vancomycin in endotoxemic rats.

Authors:  M Ngeleka; P Auclair; D Tardif; D Beauchamp; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

5.  Mycobacterium avium-M. intracellulare and Acquired Immunodeficiency Syndrome.

Authors:  E Wolinsky; C R Horsburgh; D L Cohn; R B Roberts; H Masur; R Miller; A Y Tsang; M D Iseman
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

Review 6.  Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response.

Authors:  D E Nix; S D Goodwin; C A Peloquin; D L Rotella; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

7.  Protective role of erdosteine on vancomycin-induced oxidative stress in rat liver.

Authors:  Mehmet Sahin; Hakan Cam; Seref Olgar; Sevket Ercan Tunc; Cagatay Arslan; Efkan Uz; H Ramazan Yilmaz
Journal:  Mol Cell Biochem       Date:  2006-05-30       Impact factor: 3.396

8.  Influence of daptomycin on staphylococcal abscesses and experimental tobramycin nephrotoxicity.

Authors:  C A Wood; H C Finkbeiner; S J Kohlhepp; P W Kohnen; D N Gilbert
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

9.  Ceftriaxone protects against tobramycin nephrotoxicity.

Authors:  D Beauchamp; G Thériault; L Grenier; P Gourde; S Perron; Y Bergeron; L Fontaine; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

10.  Subcellular distribution of daptomycin given alone or with tobramycin in renal proximal tubular cells.

Authors:  D Beauchamp; P Gourde; M Simard; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.